Shattuck Labs, Inc. (STTK)

Last Closing Price: 4.55 (2026-11-19)

Company Description

Shattuck Labs Inc. is a clinical-stage biotechnology company. It engages in development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of cancer and autoimmune disease. The company's wholly owned program includes SL-172154. It operates principally in Durham, North Carolina and Austin, Texas. Shattuck Labs Inc. is based in Austin, United States.

Financials, Fundamental Metrics & Ratios
Revenue (Most Recent Fiscal Year) $1.00M
Net Income (Most Recent Fiscal Year) $-48.81M
PE Ratio (Current Year Earnings Estimate) --
PE Ratio (Trailing 12 Months) --
PEG Ratio (Long Term Growth Estimate) --
Price to Sales Ratio (Trailing 12 Months) --
Price to Book Ratio (Most Recent Quarterly Book Value per Share) 2.32
Price to Cash Ratio (Most Recent Annual Cash Flow per Share) --
Pre-Tax Margin (Trailing 12 Months) -5256.80%
Net Margin (Trailing 12 Months) --
Return on Equity (Trailing 12 Months) -46.46%
Return on Assets (Trailing 12 Months) -43.56%
Current Ratio (Most Recent Fiscal Quarter) 15.80
Quick Ratio (Most Recent Fiscal Quarter) 15.80
Debt to Common Equity (Most Recent Fiscal Quarter) 0.00
Inventory Turnover (Trailing 12 Months) --
Book Value per Share (Most Recent Fiscal Quarter) $1.90
Earnings per Share (Most Recent Fiscal Quarter) $-0.14
Earnings per Share (Most Recent Fiscal Year) $-0.70
Diluted Earnings per Share (Trailing 12 Months) $-0.51
Stock
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Common Shares Outstanding 101.84M
Free Float 92.89M
Market Capitalization $455.24M
Average Volume (Last 20 Days) 1.00M
Beta (Past 60 Months) 1.21
Percentage Held By Insiders (Latest Annual Proxy Report) 8.79%
Percentage Held By Institutions (Latest 13F Reports) 58.74%
Annual Dividend (Based on Last Quarter) $0.00
Dividend Yield (Based on Last Quarter) 0.00%